Regulus Therapeutics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 30
- Market Cap
- $117.8M
- Introduction
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Clinical Trials
12
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
- Conditions
- Autosomal Dominant Polycystic Kidney DiseaseADPKDPolycystic Kidney, Autosomal Dominant
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Regulus Therapeutics Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT05521191
- Locations
- 🇺🇸
Centricity Research Phoenix Multispecialty, Mesa, Arizona, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Yale Nephrology Outpatient Clinic, New Haven, Connecticut, United States
A Study of RGLS8429 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo volume-matching RGLS8429 dose
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Regulus Therapeutics Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05429073
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Regulus Therapeutics Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT04536688
- Locations
- 🇺🇸
Balboa Nephrology Medical Group, La Mesa, California, United States
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
🇺🇸Yale Nephrology Clinical Research, New Haven, Connecticut, United States
News
Novartis Acquires Tourmaline Bio for $1.4 Billion to Advance Anti-Inflammatory Cardiovascular Therapy
Novartis agreed to acquire New York-based biotech Tourmaline Bio for $1.4 billion, paying $48 per share in cash, representing a 60% premium to the company's Monday closing price.
Renasant Bio Raises $54.5M to Develop Novel Ion Channel Therapies for ADPKD
Renasant Bio secured $54.5 million in seed funding from investors including 5AM Ventures, Atlas Venture, OrbiMed and Qiming Venture Partners USA to develop treatments for autosomal dominant polycystic kidney disease (ADPKD).
Investor Lawsuit Challenges Novartis' $1.7 Billion Acquisition of Regulus Therapeutics Over Kidney Disease Drug
A shareholder lawsuit seeks to block Novartis' acquisition of Regulus Therapeutics, alleging the deal primarily benefits company insiders rather than public stockholders.
Novartis Launches $7 Tender Offer for Regulus Therapeutics with Additional Regulatory Milestone Payment
Novartis has commenced a tender offer to acquire all outstanding shares of Regulus Therapeutics for $7.00 per share in cash plus one contingent value right per share.
Novartis Acquires Regulus Therapeutics for $800M, Expanding Kidney Disease Portfolio
Novartis has agreed to acquire Regulus Therapeutics for $800 million upfront, with potential additional payments of up to $900 million tied to regulatory milestones.
Big Pharma M&A Activity Surges as Companies Target Undervalued Biotechs Amid Market Recovery
Pharmaceutical M&A activity is experiencing a significant rebound with major deals including Novartis's $1.7 billion acquisition of Regulus Therapeutics and Merck KGaA's $3.9 billion purchase of SpringWorks Therapeutics.
Robust Pipeline of 80+ Therapies Advancing for Chronic Kidney Disease Treatment in 2025
DelveInsight's 2025 report reveals a robust pipeline with 75+ companies developing 80+ therapies for chronic kidney disease, highlighting significant industry investment in addressing this growing health concern.
Global Polycystic Kidney Disease Clinical Trials Landscape Mapped in Comprehensive 2025 Review
New comprehensive report provides critical insights into the global clinical trial landscape for Polycystic Kidney Disease, covering regional distribution, trial phases, and sponsor involvement across G7 and E7 countries.
Regulus Therapeutics' Farabursen Shows Promise in ADPKD Phase 1b Trial and Gains FDA Agreement on Phase 3 Design
Regulus Therapeutics announced positive topline results from an interim analysis of the Phase 1b MAD study of farabursen for ADPKD.
Regulus Therapeutics Reports Mixed Results for ADPKD Program, Shares Drop 24%
Regulus Therapeutics' stock experienced a significant 24% decline following the announcement of interim analysis results for their ADPKD treatment program.